TVRD · Tvardi Therapeutics, Inc.
The AI's read
The FDA response gives Tvardi a clearer path to prepare its next study and lets it consider ulcerative colitis and Crohn’s disease. The analysis compares exposure in healthy volunteers with lab measurements. It suggests TTI-109 may block STAT3 while mostly sparing STAT1 and STAT5, but does not prove this effect in patients. Together, these steps move the program forward, but a Phase 2 study still depends on FDA clearance and more funding. Safety in people with inflammatory bowel disease has not been established.